From a sample of 1,824 patients with coronary artery disease (CAD) at the time of their interview, 827 males (M) and 251 females (F), had at least one distinct recurrence of their disease—some type of angina (A) or myocardial infarction (MI). In these patients, the age and type of CAD at the first and second manifes tations (MSs) were noted, together with the patient's compliance to pre scribed therapy. The first MF of CAD in Ms was A in 61% at the age of 59.4±10.15 years and MI in 39% at a significantly younger age (54.4±10.54 years, p < 0.001). In Ms with A, the second MF was again A in 39% at the age of 61.4±10.14 years and MI in 61% at 62.1±10.2 years. In Ms with MI, the second MF was A in 85% at 56.5±10.52 years and MI in 15% at 59.2±12.0 years. No statis tical difference was found between patients with good or poor compli ance to therapy in connection with the time of the second MF as A or MI. A significantly lower percentage of MI after A, as the first MF, was found in patients with good compli ance (55%) than in patients with poor compliance (69%, p < 0.01). In Fs the first MF was A in 88% at 61.6±9.82 years and MI in 12% at 58.1±9.1 years (p < 0.05). The second MF for all F patients was MI in 48% at 65.4±10.02 years, compared with A in 52% at the age of 64.5±9.78 years. Conclusions: In Ms a rather quick (≅2.5 years) progression of CAD is expected after its initial MF mainly as A (≅ 61 %), and in these, MI as the second MF is more common in pa tients with poor compliance to ther apy. In Fs there is a delayed first MF mainly as A (≅90%) and a delayed second MF as A and MI in equal pro portion.
Get full access to this article
View all access options for this article.
References
1.
Blankenhorn DH: The prevention, deceleration and possible regression of coronary atherosclerosis . In: The Heart: Update III, ed. by Hurst JW.New York: McGraw-Hill , 1980, p 23.
2.
Blankenhorn DH: Studies of regression/progression of atherosclerosis in man. In: Atherosclerosis: Metabolic, Morphologic and Clinical Aspects, ed. by Manning GW, Haust DH. (Adv Exp Med Biol) New York: Plenum Press, 82:453, 1977.
3.
Blankenhorn DH, Nessim SA, Johnson RL, et al: Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA257:3233-3240, 1987.
4.
Buchald H., Moore RB, Varco RL: The partial ileal bypass operation in treatment of hyperlipidemias. In: Atherosclerosis: Metabolic, Morphologic and Clinical Aspects, ed. by Kritchevsky D, Paleotti R, Halmes W. (Adv Exp Med Biol) New York: Plenum Press, 63:221, 1975.
5.
Zelis R., Mason DT, Braunwald E., et al: Effects of hyperlipoproteinemias and their treatment on the peripheral circulation. J Clin Invest49:1007-1015, 1970.
6.
Zelis R., Wenger N.: Prevention of coronary Atherosclerosis. In: The Heart, ed. by Hurst JW.McGraw-Hill , 1982, p 959.
7.
Shephard RJ: Recurrence of myocardial infarction in an exercising population. Br Heart J41:133-138, 1979.
8.
Levy RJ: Hyperlipoproteinemia and its management. J Cardiovas Med5:435-439, 1980.
9.
TheNorwegian Multicentre Study Group: Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med304:801-807, 1981.
10.
Darsinos J. , Pistevos A., Karli J., et al: First clinical manifestation of coronary artery disease and its relationship to main risk factors. Hellenic Cardiological Rev (Athens) 26:216-224, 1985.
11.
Kannel WB, Feinleib M.: Natural history of angina pectoris in the Framingham Study. Prognosis and survival. Am J Cardiol29:154-163, 1972.
12.
The CoronaryDrug Project: Factors influencing longterm prognosis after recovery from myocardial infarction. Three-year findings of the Coronary Drug Project. J Chron Dis27:267, 1974.
13.
Kallio V., Hamalainen H., Hakkila J., et al: Reduction in sudden deaths by a multifactorial intervention programme after acute myocardial infarction. Lancet2:1091-1097, 1979.
